LAMA/LABA Combination (e.g., Umeclidinium/Vilanterol)
Treatment for Copd
Typical Dosage: Umeclidinium 62.5 mcg/Vilanterol 25 mcg once daily
Effectiveness
85%
Safety Score
55%
Clinical Trials
50
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Umeclidinium 62.5 mcg/Vilanterol 25 mcg once daily
Time to Effect
15-30 minutes (bronchodilation), days-weeks (symptoms)
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,400
Monitoring:$800
Side Effect Mgmt:$100
Total Annual:$6,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$9,000
Comparison vs Tiotropium (LAMA monotherapy)
Cost Difference
+$1,200/year
More expensive
QALY Difference
+0.03 QALYs
Better outcomes
Dominance
No dominance
LAMA/LABA Combination (e.g., Umeclidinium/Vilanterol) Outcomes
for Copd
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+70%
Common Side Effects
Nasopharyngitis
+10%
Headache
+8%
Upper respiratory tract infection
+7%
Cough
+5%
Dry mouth
+3%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov